AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: We recently synthesized and discovered a new compound (17f) that inhibits STAT5 phosphorylation and transcriptional activity in various CML and AML cells, without detectable effects on other signal transduction molecules, such as STAT3 and the protein kinases ERK1/2 and AKT [23].